targeted radionuclide therapy有针对性的放射性核素治疗.pdf

Cancers 2011, 3, 3838-3855; doi:10.3390/cancers3043838 OPEN ACCESS cancers ISSN 2072-6694 /journal/cancers Review Targeted Radionuclide Therapy Devrim Ersahin *, Indukala Doddamane and David Cheng Department of Diagnostic Radiology, School of Medicine, Yale University, 333 Cedar St., New Haven, CT 06520, USA; E-Mails: indukala.doddamane@ (I.D.);david.cheng@ (D.C.) * Author to whom correspondence should be addressed; E-Mail: devrimersahin@; Tel.: +1-215-290-5917; Fax: +1-203-200-5054. Received: 22 August 2011; in revised form: 27 September 2011 / Accepted: 27 September 2011 / Published: 11 October 2011 Abstract: Targeted radiotherapy is an evolving and promising modality of cancer treatment. The killing of cancer cells is achieved with the use of biological vectors and appropriate radionuclides. Among the many advantages of this approach are its selectiveness in delivering the radiation to the target, relatively less severe and infrequent side effects, and the possibility of assessing the uptake by the tumor prior to the therapy. Several different radiopharmaceuticals are currently being used by various administration routes and targeting mechanisms. This article aims to briefly review the current status of targeted radiotherapy as well as to outline the advantages and disadvantages of radionuclides used for this purpose. Keywords: targeted radiotherapy; radionuclide; radioimmunotherapy 1. Introduction The development and evolution of modern chemotherapy during t